1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Feasibility and utility of synthetic control arms derived from real-world data to support clinical development
    Meeting Abstract

    Lyman, J. P.; Doucette, A.; Zheng-Lin, B.; Cabanski, C. R.; Maloy, M. A.; Bayless, N. L.; Xu, J.; Smith, W.; Karakunnel, J. J.; Fairchild, J. P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer
    Meeting Abstract

    Lumish, M. A.; Cohen, J. L.; Stadler, Z. K.; Weiss, J. A.; Lamendola-Essel, M. F.; Yaeger, R.; Segal, N. H.; El Dika, I. H.; Saltz, L. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study
    Meeting Abstract

    Kopetz, S.; Murphy, D. A.; Pu, J.; Yaeger, R.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Elez, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Yaeger, R.; Ciardiello, F.; Desai, J.; Kim, T. W.; Maughan, T.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Meeting Abstract

    Kelley, R. K.; Van Cutsem, E.; Lee, M. S.; Wolf, I.; Fakih, M.; de Vos-Geelen, J.; Lee, V.; Vogel, A.; Wu, X. L.; Jin, F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Yoshino, T.; Kim, T. W.; Desai, J.; Yaeger, R.; Van Cutsem, E.; Ciardiello, F.; Wasan, H. S.; Maughan, T.; Zhang, Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PASS-01: Pancreatic adenocarcinoma signature stratification for treatment-01
    Meeting Abstract

    Knox, J. J.; Jaffee, E. M.; O'Kane, G. M.; Plenker, D.; Zhang, A.; Ramotar, S.; Dodd, A.; Prince, R. M.; Laheru, D.; Yu, K. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01
    Meeting Abstract

    Javle, M. M.; Abou-Alfa, G. K.; Macarulla, T.; Personeni, N.; Adeva, J.; Bergamo, F.; Malka, D.; Vogel, A.; Knox, J. J.; Jeffry Evans, T. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of bevacizumab-based treatment in early-onset treatment-naive metastatic colorectal cancer patients: An ARCAD database analysis
    Meeting Abstract

    Jin, Z.; Dixon, J. G.; Hubbard, J. M.; Eng, C.; Lieu, C. H.; Fiskum, J.; Saltz, L. B.; Hurwitz, H. I.; Venook, A. P.; Schmoll, H. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Janjigian, Y. Y.; Oh, D. Y.; Rha, S. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; Di Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; Stein, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save